

Tentative Outline
Anti-Cancer Agents in Medicinal Chemistry
Guest Editor(s): Harmeet Kaur

TITLE: Role of Hetroaromatics as Anticancer Agents

Aims & Scope: The study of heterocycles is an evergreen field in the branch of medicinal chemistry and always attract the attention of chemists working not only in the area of synthetic chemistry but also in the natural products. Many useful drugs have emerged from the successful investigation carried out in this branch and heterocyclic compounds are important pharmacophores among these. Various heterocyclics like benzimidazole, pyrimidine, indole *etc.* are also structural isosteres of nucleotides responsible for interaction with biopolymers and pharmacological activities. Heterocycles are structural part of wide variety of drugs, vitamins, natural products, biomolecules, and biologically active compounds, and agrochemicals. Heterocycles are also of considerable interest due to their synthetic utility as synthetic intermediates, protecting groups, chiral auxiliars, catalysts, and metal ligands in asymmetric catalytic inorganic synthesis. More than 80% of new drugs contain heterocycles and the interface between chemistry and biology, at which so much new scientific insight, discovery and application is taking place is crossed by heterocyclic compounds. This issue will cover the most active heterocycles having considerable anticancer activities. In addition, new molecular targets in cancer, targetable molecules in cancer signaling pathways, and their eventual application in drug development and therapeutics will also be discussed. New opportunities, for researchers, to synthesize new heterocyclic compounds having anticancer activities will also be cited alongwith future aspects of these compounds as anticancer agents.

Key words: Anticancer, Benzimidazole, Diazenyl, Molecular Target

Subtopics: Proposed Titles (These titles are tentative titles and further more titles can be added.)

- 1. Role of benzimidazole derivatives as anticancer agents**
- 2. Diazenyl derivatives and their complexes as anticancer agents**

3. **Thiazoldine derivatives as anticancer agents**
4. **Hetrocyclic Drug – polymer conjugates for cancer target drug delivery**
5. **Antisense therapeutics interventions for Molecular Biological Targets in Cancer**
6. **Current Therapies and Novel Targets in Breast cancer**

Schedule:

Manuscript submission deadline: 3-4 Months

Peer Review Due: 1 Month

Revision Due: 20-25 days

Notification of acceptance by the Guest Editor: Within 10

days Final manuscripts due: **October 2015**